首页> 外文期刊>Genes and Development: a Journal Devoted to the Molecular Analysis of Gene Expression in Eukaryotes, Prokaryotes, and Viruses >miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy
【24h】

miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy

机译:miR-424(322)/ 503是乳腺癌肿瘤抑制器,其损失促进抗化疗抗性

获取原文
获取原文并翻译 | 示例
           

摘要

The female mammary gland is a very dynamic organ that undergoes continuous tissue remodeling during adulthood. Although it is well established that the number of menstrual cycles and pregnancy (in this case transiently) increase the risk of breast cancer, the reasons are unclear. Growing clinical and experimental evidence indicates that improper involution plays a role in the development of this malignancy. Recently, we described the miR-424(322)/503 cluster as an important regulator of mammary epithelial involution after pregnancy. Here, through the analysis of similar to 3000 primary tumors, we show that miR-424(322)/503 is commonly lost in a subset of aggressive breast cancers and describe the genetic aberrations that inactivate its expression. Furthermore, through the use of a knockout mouse model, we demonstrate for the first time that loss of miR-424(322)/503 promotes breast tumorigenesis in vivo. Remarkably, we found that loss of miR-424(322)/503 promotes chemoresistance due to the up-regulation of two of its targets: BCL-2 and insulin-like growth factor-1 receptor (IGF1R). Importantly, targeted therapies blocking the aberrant activity of these targets restore sensitivity to chemotherapy. Overall, our studies reveal miR-424(322)/503 as a tumor suppressor in breast cancer and provide a link between mammary epithelial involution, tumorigenesis, and the phenomenon of chemoresistance.
机译:雌性乳腺是一种非常动态的器官,在成年期间经历连续的组织重塑。虽然已经很好地确定了月经周期和怀孕的数量(在这种情况下瞬间)增加了乳腺癌的风险,但原因尚不清楚。越来越多的临床和实验证据表明,不当的涉及在这种恶性肿瘤的发展中发挥作用。最近,我们将MiR-424(322)/ 503簇描述为怀孕后的乳腺上皮涉及的重要调节剂。这里,通过分析类似于3000个原发性肿瘤,我们表明miR-424(322)/ 503通常在侵袭性乳腺癌的子集中丢失,并描述了灭活其表达的遗传像差。此外,通过使用敲除小鼠模型,我们首次证明MIR-424(322)/ 503的丧失促进体内乳腺肿瘤内酯。值得注意的是,我们发现MiR-424(322)/ 503的损失由于其两个靶标的上调:Bcl-2和胰岛素样生长因子-1受体(IGF1R),促进了化学渗透性。重要的是,靶向疗法阻断这些靶标的异常活性恢复对化疗的敏感性。总体而言,我们的研究将MiR-424(322)/ 503显示为乳腺癌中的肿瘤抑制,并提供乳腺上皮和肿瘤内膜瘤和化学抑制现象之间的联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号